Senhwa Biosciences, Inc., a clinical stage drug development company focused on next generation DNA Damage Response (DDR) therapeutics for the treatment of cancer. Currently 2 main compounds CX-5461 and CX-4945 are both first- in- class small molecule drugs and ongoing phase I/II clinical trials in Australia, Canada, United States, Korea and Taiwan. Senhwa’s CX-5461 is a G-quadruplexes (G4) stabilizer, causing DNA damage of tumor cells through a synthetic lethality (SL) approach in patients with BRCA1/2 mutations or HR deficiency (HRD). Senhwa's CX-4945 is a selective CK2 inhibitor and it has been shown to inhibit the phosphorylation of the DNA repair protein XRCC1 and subsequently enhance the activity of DNA damaging chemotherapy agents. Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global investigators and service providers.
View Top Employees from Senhwa Biosciences, Inc.Website | http://www.senhwabio.com/ |
Revenue | $7 million |
Employees | 34 (34 on RocketReach) |
Founded | 2012 |
Address | 10509 Vista Sorrento Parkway Suite 201, San Diego, California 92121, US |
Phone | (858) 552-6808 |
Fax | (858) 552-6811 |
Technologies | |
Industry | Biotechnology, Targeted Cancer Therapy, Pharmaceuticals, Drug Development, Healthcare |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies |
Looking for a particular Senhwa Biosciences, Inc. employee's phone or email?
The Senhwa Biosciences, Inc. annual revenue was $7 million in 2024.
John Soong is the Chief Medical Officer of Senhwa Biosciences, Inc..
34 people are employed at Senhwa Biosciences, Inc..
Senhwa Biosciences, Inc. is based in San Diego, California.
The NAICS codes for Senhwa Biosciences, Inc. are [32541, 32, 3254, 325].
The SIC codes for Senhwa Biosciences, Inc. are [283, 28].